Le Lézard
Classified in: Health, Science and technology
Subject: PLW

Vivace Therapeutics Announces Issuance of New U.S. Composition of Matter Patents


SAN MATEO, Calif., Feb. 3, 2022 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, today announced that the United States Patent and Trademark Office (USPTO) has issued the company two new composition of matter patents. The newly issued patents, U.S. No. 11,186,554 and U.S. No. 11,192,865, are directed at novel, first-in-class, anti-cancer compounds discovered by Vivace that target the Hippo pathway.

"We have undertaken a thoughtful and strategic approach to building a strong intellectual property estate that offers appropriate protection for the pioneering work we have conducted in understanding the Hippo pathway and creating proprietary compounds that have the ability to fight cancer by impacting this pathway," said Sofie Qiao, Ph.D., chief executive officer of Vivace Therapeutics. "The issuance of these patents supports our continued work aimed at delivering first-in-class treatments to patients battling cancer."

Vivace's proprietary compounds inhibit palmitoylation of members of the transcriptional enhanced associate domain (TEAD) protein family, including both covalent and non-covalent inhibitors. The company's clinical candidate, VT3989, is currently in Phase 1 clinical trials. Pre-clinical research and development activities have demonstrated that the clinical candidate is active as a monotherapy and in combination with other anti-cancer therapies against tumors that rely upon dysfunction of the Hippo pathway.

About Vivace Therapeutics, Inc.
Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing a first-in-class approach to treat human carcinomas of high unmet medical need. Based in San Francisco Bay Area, the company has raised $70 million to date, and is funded by leading biotechnology investors, including Canaan Partners, WuXi Healthcare Ventures, Cenova Capital, Sequoia Capital China, Boxer Capital and RA Capital Mangement. For more information, please visit www.vivacetherapeutics.com.

Contact information
Sofie Qiao, Ph.D.
President and CEO
[email protected]
650.666.2753

Tim Brons
Vida Strategic Partners (media)
646-319-8981
[email protected]

SOURCE Vivace Therapeutics, Inc.


These press releases may also interest you

at 12:50
First Clinical Trial Results of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy Presented at International Myology 2024 Congress
Today, Professor Francesco Muntoni, principal investigator of the international multicenter gene therapy trial for Duchenne Muscular Dystrophy with GNT0004 product, sponsored by Genethon, presented the innovative trial design and its initial results...

at 12:37
Clinical Trials in Australia: Recommendations for Maximizing Collaboration between China and Australia, Upcoming Webinar Hosted by Taimei Technology
In this free webinar, attendees will gain insights into the clinical trial landscapes in China and Australia and discover practical strategies for maximizing collaboration and ensuring successful outcomes. This includes identifying common areas of...

at 12:36
Nurse Well-Being the Focus of Engage, Powered By ENA-Golisano Children's Hospital Partnership
Engage, Powered by ENA, on Tuesday announced a new partnership with Golisano Children's Hospital of Southwest Florida's emergency department that centers on enhancing the well-being and professional growth of emergency nurses who play an integral...

at 12:35
PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of Legal
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and...

at 12:30
University of Washington School of Medicine AIMS Center and Concert Health to Scale Telepsychiatry Collaborative Care for Complex Psychiatric Disorders
Concert Health, the leading Collaborative Care platform, and the Advancing Integrated Mental Health Solutions (AIMS) Center in the University of Washington Department of Psychiatry and Behavioral Sciences, today announced a three year, multi-state...

at 12:30
Key Considerations for Cell Therapy Trials Beyond Oncology, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn the essential infrastructure requirements necessary for clinical sites to effectively manage cell therapy products in non-oncology clinical trials. Attendees will learn the key considerations in patient selection criteria...

More news about Health...


News published on and distributed by: